Table 2.
Associations between hypermethylated and hypomethylated CpG sites and clinicopathological features
| Post-op survival | Lymph node metastasis | Tumor size | Lauren classification | Metaplasia | Atrophy | H. pylori | |
|---|---|---|---|---|---|---|---|
| CpgID/Gene promoter Hypermethylated in the tumor | |||||||
| cg09350274/GFRA3 | r = −0.69 p = 0.002 | r = 0.52 p = 0.028 | r = 0.48 p = 0.42 | r = 0.480 p = 0.044 | r = −0.590 p = 0.01 | ||
| cg02720618/ESR1 | r = 0.56 p = 0.016 | ||||||
| cg04623837/HCG9 | r = 0.64 p = 0.004 | ||||||
| cg07307078/TUBB6 | r = 0.49 p = 0.04 | ||||||
| cg08615333/TGFB3 | r = 0.5 p = 0.037 | r = 0.504 p = 0.033 | |||||
| cg01566170/CAPN2 | r = −0.53 p = 0.023 | r = 0.526 p = 0.025 | |||||
| cg16986846/SCGB2A1 | r = −0.576 p = 0.012 | ||||||
| cg02633817/FXYD3 | r = −0.474 p = 0.047 | ||||||
| cg20640433/LAMA2 | r = 524 p = 0.026 | ||||||
| cg21905630/GSH2 | r = 0.52 p = 0.028 | ||||||
| cg13718960/RNASE1 | r = 0.554 p = 0.017 | ||||||
| cg19118812/ELMO1 | r = −0.546 p = 0.019 | ||||||
| cg26557658/FAM43B | r = −0.604 p = 0.008 | ||||||
| cg03616357/FLJ21159 | r = 0.574 p = 0.013 | ||||||
| cg08615333/TGFB3 | r = 0.504 p = 0.033 | ||||||
| cg14189571/ZFP42 | r = 0.484 p = 0.042 | ||||||
| cg17872757/FLI1 | r = 0.495 p = 0.037 | ||||||
| cg21790626/ZNF154 | r = 0.573 p = 0.013 | ||||||
| cg27546237/COL4A1 | r = 0.527 p = 0.025 | ||||||
| CpgID/Gene promoter Hypomethylated in the tumor | |||||||
| cg13694749/SCN4A | r = −0.638 p = 0.004 | ||||||
| cg18059088/HS3ST1 | r = −0.474 p = 0.047 | ||||||
| cg26619317/CNN3 | r = 0.481 p = 0.043 | ||||||
| cg07131544/NCR2 | r = 0.496 p = 0.036 | ||||||
| cg14696870/FCER1A | r = −0.567 p = 0.014 | ||||||
| cg20676475/LCE3D | r = −0.708 p = 0.001 | ||||||
| cg00974864/FCGR3B | r = −562 p = 0.015 | ||||||
| cg13180098/RHO | r = −0.604 p = 0.008 | r = −0.597 p = 0.009 | r = 0.682 p = 0.002 | ||||
| cg24691453/S100A4 | r = 0.470 p = 0.49 | ||||||
| cg15309006/LOC63928 | r = −0.499 p = 0.035 | ||||||
| cg26789453/TMEM116 | r = −0.512 p = 0.030 | ||||||
| cg26264314/NALP5 | r = −0.474 p = 0.047 | ||||||
| cg20383064/BFSP2 | r = −0.487 p = 0.040 | ||||||
| cg25119415/MNDA | r = −0.646 p = 0.004 | r = −0.514 p = 0.029 | r = 0.547 p = 0.019 | ||||
| cg14603345/BTBD3 | p = −0.483 r = 0.042 | ||||||
| cg17356733/IFNGR2 | r = −0.480 p = 0.044 | ||||||
| cg23756272/BCL2 | r = −0.500 p = 0.035 | ||||||
| cg00842351/TJP2 | r = −527 p = 0.24 | ||||||
| cg25248094/SH2D1A | r = 0.487 p = 0.041 | r = −0.526 p = 0.025 | |||||
| cg04454050/TREML1 | 0.474 0.047 | ||||||
| cg02611419/KCNK17 | r = −502 p = 0.034 | ||||||
| cg05252264/FCAR | r = 0.587 p = 0.10 | ||||||
| cg22268164/TRHR | r = −0.619 p = 0.006 | ||||||
| cg02046017/LOC220070 | r = 0.475 p = 0.046 | ||||||
| cg09191232/PAPSS1 | r = −0.581 p = 0.011 |
The filtered list of 100 hypermethylated and 100 hypomethylated CpG sites were compared to associated gene expression. 19 of the hypermethylated CpG sites and 25 of the hypomethylated CpG sites showed significant correlation with one or more of the clinicopathological parameters (Pearson correlation coefficients (r) and significance levels (p) are listed)